Search Results 391-400 of 36425 for Ovary
The purpose of this study is to determine the extent to which PARP inhibitor (PARPi) treatment reduces systemic levels of mesenchymal stem cell (MSC)-derived ...
This phase II trial studies how well Avatar-directed chemotherapy works in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that ...
The purpose of this study is to compare the progression-free survival in women who have platinum-resistant ovarian cancer, who receive combination therapy ...
About this study. Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. Participation eligibility.
When Jean Niven learned she had ovarian cancer, her desire to find a knowledgeable, compassionate physician led her to Mayo Clinic. Then, when her cancer ...
The purpose of this study is to identify the measurement of anti-mullerian hormone present that can specifically identify a 90% prediction of a poor ovarian ...
The study population is adult patients with asymptomatic recurrent ovarian cancer who have an elevation in their CA-125 level. Participation eligibility.
Ovarian cancer is the most common cause of death from gynecological cancers in the U.S.. In their study, Dr. Goode and her collaborators showed that variations ...
The purpose of this Phase 1a/1b study of SC-003 in patients with platinum-resistant/refractory ovarian cancer is to characterize the safety and tolerability ...
A Study to Investigate the Safety and Effectiveness of FE 999049 in Controlled Ovarian Stimulation in Women Aged 35-42 Years Old ... Known tumors of the ovary, ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.